These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
70 related articles for article (PubMed ID: 15644476)
1. Minocycline has no effect on the fibrinolytic activity of alteplase. Farooq MU; Zemke D; Majid A Ann Pharmacother; 2005 Feb; 39(2):387-8. PubMed ID: 15644476 [No Abstract] [Full Text] [Related]
2. Alfimeprase to succeed Genentech's alteplase? Vastag B Nat Biotechnol; 2006 Aug; 24(8):875-6. PubMed ID: 16900112 [No Abstract] [Full Text] [Related]
4. Tissue plasminogen activator in cardiac arrest with pulseless electrical activity. Böttiger BW; Padosch SA; Wenzel V N Engl J Med; 2002 Oct; 347(16):1281-2; author reply 1281-2. PubMed ID: 12393830 [No Abstract] [Full Text] [Related]
5. Efficacy and safety of intrapleural instillation of alteplase in the management of complicated pleural effusion or empyema. Thommi G; Nair CK; Aronow WS; Shehan C; Meyers P; McLeay M Am J Ther; 2007; 14(4):341-5. PubMed ID: 17667208 [TBL] [Abstract][Full Text] [Related]
7. Changes in blood viscosity with the recombinant tissue plasminogen activator alteplase. Hitosugi M; Omura K; Yufu T; Kido M; Niwa M; Nagai T; Tokudome S Thromb Res; 2007; 120(3):447-50. PubMed ID: 17064755 [TBL] [Abstract][Full Text] [Related]
8. Tissue plasminogen activator approved for stroke. Barber A; Gommans J N Z Med J; 2005 May; 118(1214):U1432. PubMed ID: 15886728 [No Abstract] [Full Text] [Related]
9. Thrombolytic therapy with alteplase for ischaemic stroke. Drug Ther Bull; 2009 Feb; 47(2):14-8. PubMed ID: 19193701 [TBL] [Abstract][Full Text] [Related]
10. Tissue plasminogen activator does not benefit most eligible patients with stroke. Lansberg MG; Schwartz NE Arch Neurol; 2009 Apr; 66(4):540-1; author reply 541. PubMed ID: 19364946 [No Abstract] [Full Text] [Related]
11. Alteplase for the management of occluded central venous access devices: safety considerations. Smith LH Clin J Oncol Nurs; 2008 Feb; 12(1):155-7. PubMed ID: 18258586 [No Abstract] [Full Text] [Related]
12. Can the therapeutic window for tissue plasminogen activator be extended to 6 hours after stroke onset? Alexandrov AV Nat Clin Pract Cardiovasc Med; 2005 Jul; 2(7):342-3. PubMed ID: 16265558 [No Abstract] [Full Text] [Related]
13. Alteplase for the treatment of central venous catheter occlusion in children: results of a prospective, open-label, single-arm study (The Cathflo Activase Pediatric Study). Blaney M; Shen V; Kerner JA; Jacobs BR; Gray S; Armfield J; Semba CP; J Vasc Interv Radiol; 2006 Nov; 17(11 Pt 1):1745-51. PubMed ID: 17142704 [TBL] [Abstract][Full Text] [Related]
14. PPACK-Desmodus rotundus salivary plasminogen activator (cDSPAalpha1) prevents the passage of tissue-type plasminogen activator (rt-PA) across the blood-brain barrier and neurotoxicity. Roussel BD; Hommet Y; Macrez R; Schulz T; Petersen KU; Berezowski V; Cecchelli R; Ali C; Vivien D Thromb Haemost; 2009 Sep; 102(3):606-8. PubMed ID: 19718485 [No Abstract] [Full Text] [Related]